|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 2,900.00 JPY | +1.59% |
|
+3.20% | -13.38% |
| 03-09 | AstraZeneca and Daiichi Sankyo Enter Global Collaboration to Jointly Develop and Commercialize Enhertu | CI |
| 03-09 | UK Shares Start Week in Red as Oil Prices Surge Amid US-Iran War | MT |
| Fiscal Period: March | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
Profitability | ||||||||||
Return on Assets | 1.9 | 2.12 | 2.69 | 4.43 | 5.64 | |||||
Return on Total Capital | 2.6 | 2.98 | 3.98 | 7.59 | 10.76 | |||||
Return On Equity % | 5.88 | 5.11 | 7.81 | 12.83 | 17.86 | |||||
Return on Common Equity | 5.89 | 5.11 | 7.81 | 12.81 | 17.86 | |||||
Margin Analysis | ||||||||||
Gross Profit Margin % | 64.85 | 66.19 | 71.57 | 74.07 | 77.96 | |||||
SG&A Margin | 34.6 | 34.29 | 36.86 | 39.77 | 38.76 | |||||
EBITDA Margin % | 12.59 | 12.56 | 13.27 | 16.93 | 20.18 | |||||
EBITA Margin % | 6.63 | 6.99 | 7.97 | 13.2 | 16.54 | |||||
EBIT Margin % | 6.63 | 6.99 | 7.97 | 13.2 | 16.54 | |||||
Income From Continuing Operations Margin % | 7.88 | 6.41 | 8.54 | 12.55 | 15.68 | |||||
Net Income Margin % | 7.89 | 6.41 | 8.54 | 12.53 | 15.68 | |||||
Net Avail. For Common Margin % | 7.89 | 6.41 | 8.54 | 12.53 | 15.68 | |||||
Normalized Net Income Margin | 4.87 | 4.52 | 5.57 | 9.27 | 11.27 | |||||
Levered Free Cash Flow Margin | 13.17 | 25.97 | -15.16 | -11.54 | 19.69 | |||||
Unlevered Free Cash Flow Margin | 13.29 | 26.09 | -15.05 | -11.46 | 19.77 | |||||
Asset Turnover | ||||||||||
Asset Turnover | 0.46 | 0.49 | 0.54 | 0.54 | 0.55 | |||||
Fixed Assets Turnover | 3.76 | 3.67 | 3.92 | 4.16 | 4.1 | |||||
Receivables Turnover (Average Receivables) | 3.56 | 4.19 | 4.15 | 3.99 | 3.51 | |||||
Inventory Turnover (Average Inventory) | 1.81 | 1.69 | 1.4 | 1.12 | 0.87 | |||||
Short Term Liquidity | ||||||||||
Current Ratio | 3.59 | 3.4 | 2.82 | 3.05 | 2.53 | |||||
Quick Ratio | 1.73 | 2.35 | 1.49 | 1.55 | 1.67 | |||||
Operating Cash Flow to Current Liabilities | 0.54 | 0.35 | 0.22 | 0.84 | 0.07 | |||||
Days Sales Outstanding (Average Receivables) | 102.65 | 87.1 | 87.9 | 91.78 | 103.84 | |||||
Days Outstanding Inventory (Average Inventory) | 201.88 | 216.3 | 260.81 | 325.94 | 418.3 | |||||
Average Days Payable Outstanding | 283.57 | 306.62 | 305.57 | 325.38 | 421.28 | |||||
Cash Conversion Cycle (Average Days) | 20.97 | -3.22 | 43.14 | 92.34 | 100.86 | |||||
Long Term Solvency | ||||||||||
Total Debt/Equity | 17.78 | 15.81 | 13.34 | 9.24 | 9.6 | |||||
Total Debt / Total Capital | 15.1 | 13.65 | 11.77 | 8.46 | 8.76 | |||||
LT Debt/Equity | 15.45 | 13.51 | 9.72 | 8.48 | 8.67 | |||||
Long-Term Debt / Total Capital | 13.12 | 11.67 | 8.58 | 7.76 | 7.91 | |||||
Total Liabilities / Total Assets | 39 | 39.19 | 42.37 | 51.21 | 53.03 | |||||
EBIT / Interest Expense | 34.69 | 37.62 | 48.08 | 103.82 | 146.58 | |||||
EBITDA / Interest Expense | 65.89 | 67.63 | 80.06 | 133.1 | 178.84 | |||||
(EBITDA - Capex) / Interest Expense | 48.9 | 35.31 | 51.4 | 89.74 | 124.21 | |||||
Total Debt / EBITDA | 1.87 | 1.63 | 1.14 | 0.58 | 0.41 | |||||
Net Debt / EBITDA | -1.27 | -3.42 | -1.47 | -1.81 | -1.27 | |||||
Total Debt / (EBITDA - Capex) | 2.51 | 3.12 | 1.77 | 0.85 | 0.59 | |||||
Net Debt / (EBITDA - Capex) | -1.72 | -6.55 | -2.29 | -2.69 | -1.83 | |||||
Growth Over Prior Year | ||||||||||
Total Revenues, 1 Yr. Growth % | -1.96 | 8.56 | 22.36 | 25.28 | 17.77 | |||||
Gross Profit, 1 Yr. Growth % | -2.25 | 10.79 | 32.3 | 29.66 | 23.95 | |||||
EBITDA, 1 Yr. Growth % | -36.69 | 8.33 | 29.29 | 59.75 | 40.37 | |||||
EBITA, 1 Yr. Growth % | -54.04 | 14.47 | 39.58 | 107.48 | 47.49 | |||||
EBIT, 1 Yr. Growth % | -54.04 | 14.47 | 39.58 | 107.48 | 47.49 | |||||
Earnings From Cont. Operations, 1 Yr. Growth % | -41.2 | -11.68 | 63.04 | 84.1 | 47.13 | |||||
Net Income, 1 Yr. Growth % | -41.15 | -11.83 | 63.04 | 83.84 | 47.34 | |||||
Normalized Net Income, 1 Yr. Growth % | -47.78 | 0.68 | 50.74 | 108.6 | 43.1 | |||||
Diluted EPS Before Extra, 1 Yr. Growth % | -40.98 | -10.74 | 63.02 | 83.83 | 48.99 | |||||
Accounts Receivable, 1 Yr. Growth % | -25 | 14.93 | 30.91 | 30.1 | 36.31 | |||||
Inventory, 1 Yr. Growth % | 15.86 | 8.49 | 38.41 | 45.26 | 17.53 | |||||
Net Property, Plant and Equip., 1 Yr. Growth % | 7.38 | 14.62 | 14.75 | 20.86 | 18.22 | |||||
Total Assets, 1 Yr. Growth % | -0.97 | 6.53 | 12.94 | 37.95 | -0.14 | |||||
Tangible Book Value, 1 Yr. Growth % | -3.32 | 8.02 | 7.66 | 18.81 | -9.37 | |||||
Common Equity, 1 Yr. Growth % | -2.59 | 6.2 | 7.03 | 16.76 | -3.84 | |||||
Cash From Operations, 1 Yr. Growth % | -2.24 | -27.56 | -17.75 | 423.31 | -91.02 | |||||
Capital Expenditures, 1 Yr. Growth % | -2.16 | 100.79 | -3.17 | 45.39 | 31.63 | |||||
Levered Free Cash Flow, 1 Yr. Growth % | -45.56 | 114.05 | -171.41 | -4.62 | -301 | |||||
Unlevered Free Cash Flow, 1 Yr. Growth % | -45.4 | 113.07 | -170.61 | -4.63 | -303.12 | |||||
Dividend Per Share, 1 Yr. Growth % | 15.71 | 0 | 11.11 | 66.67 | 20 | |||||
Compound Annual Growth Rate Over Two Years | ||||||||||
Total Revenues, 2 Yr. CAGR % | 1.75 | 3.16 | 15.25 | 23.81 | 21.47 | |||||
Gross Profit, 2 Yr. CAGR % | 5.1 | 4.07 | 21.07 | 30.98 | 26.77 | |||||
EBITDA, 2 Yr. CAGR % | -3.41 | -17.19 | 18.35 | 43.71 | 49.75 | |||||
EBITA, 2 Yr. CAGR % | -12.7 | -27.47 | 26.4 | 70.18 | 74.94 | |||||
EBIT, 2 Yr. CAGR % | -12.7 | -27.47 | 26.4 | 70.18 | 74.94 | |||||
Earnings From Cont. Operations, 2 Yr. CAGR % | -9.9 | -27.94 | 20 | 73.25 | 64.58 | |||||
Net Income, 2 Yr. CAGR % | -9.82 | -27.97 | 19.89 | 73.13 | 64.58 | |||||
Normalized Net Income, 2 Yr. CAGR % | -7.36 | -27.49 | 23.19 | 77.33 | 72.78 | |||||
Diluted EPS Before Extra, 2 Yr. CAGR % | -9.7 | -27.42 | 20.63 | 73.11 | 65.5 | |||||
Accounts Receivable, 2 Yr. CAGR % | -25.64 | -7.16 | 22.66 | 30.5 | 33.17 | |||||
Inventory, 2 Yr. CAGR % | 6.81 | 12.11 | 22.54 | 41.79 | 30.66 | |||||
Net Property, Plant and Equip., 2 Yr. CAGR % | 7.61 | 10.94 | 14.68 | 17.76 | 19.53 | |||||
Total Assets, 2 Yr. CAGR % | -0.07 | 2.71 | 9.69 | 24.82 | 17.37 | |||||
Tangible Book Value, 2 Yr. CAGR % | 0.95 | 2.19 | 7.84 | 13.1 | 3.77 | |||||
Common Equity, 2 Yr. CAGR % | 0.89 | 1.71 | 6.61 | 11.79 | 5.96 | |||||
Cash From Operations, 2 Yr. CAGR % | 44.51 | -15.85 | -22.81 | 107.47 | -31.43 | |||||
Capital Expenditures, 2 Yr. CAGR % | -6.98 | 40.16 | 39.44 | 18.65 | 38.34 | |||||
Levered Free Cash Flow, 2 Yr. CAGR % | -30.78 | 7.95 | 23.63 | -17.47 | 38.46 | |||||
Unlevered Free Cash Flow, 2 Yr. CAGR % | -30.27 | 7.86 | 22.65 | -17.94 | 39.18 | |||||
Dividend Per Share, 2 Yr. CAGR % | 7.57 | 7.57 | 5.41 | 36.08 | 41.42 | |||||
Compound Annual Growth Rate Over Three Years | ||||||||||
Total Revenues, 3 Yr. CAGR % | 0.08 | 3.97 | 9.2 | 18.5 | 21.76 | |||||
Gross Profit, 3 Yr. CAGR % | 0.54 | 6.96 | 12.74 | 23.87 | 28.59 | |||||
EBITDA, 3 Yr. CAGR % | -0.49 | 0.36 | -3.93 | 30.79 | 42.59 | |||||
EBITA, 3 Yr. CAGR % | -5.79 | -4.45 | -9.78 | 49.11 | 62.25 | |||||
EBIT, 3 Yr. CAGR % | -5.79 | -4.45 | -9.78 | 49.11 | 62.25 | |||||
Earnings From Cont. Operations, 3 Yr. CAGR % | 8.23 | -10.5 | -5.4 | 38.4 | 64.06 | |||||
Net Income, 3 Yr. CAGR % | 8.01 | -10.5 | -5.42 | 38.25 | 64.06 | |||||
Normalized Net Income, 3 Yr. CAGR % | -3.29 | -4.76 | -7.46 | 46.84 | 65.09 | |||||
Diluted EPS Before Extra, 3 Yr. CAGR % | 8.8 | -10.05 | -4.95 | 38.82 | 64.67 | |||||
Accounts Receivable, 3 Yr. CAGR % | 0.07 | -14.02 | 4.11 | 25.09 | 32.41 | |||||
Inventory, 3 Yr. CAGR % | 5.19 | 7.37 | 20.27 | 29.69 | 33.19 | |||||
Net Property, Plant and Equip., 3 Yr. CAGR % | 6.77 | 9.9 | 12.2 | 16.71 | 17.91 | |||||
Total Assets, 3 Yr. CAGR % | 3.19 | 2.08 | 6.01 | 18.4 | 15.87 | |||||
Tangible Book Value, 3 Yr. CAGR % | 4.94 | 3.26 | 3.98 | 11.38 | 5.05 | |||||
Common Equity, 3 Yr. CAGR % | 3.93 | 2.63 | 3.45 | 9.89 | 6.32 | |||||
Cash From Operations, 3 Yr. CAGR % | 21.02 | 14.8 | -16.49 | 46.09 | -27.14 | |||||
Capital Expenditures, 3 Yr. CAGR % | 10.12 | 20.22 | 23.9 | 41.39 | 22.83 | |||||
Levered Free Cash Flow, 3 Yr. CAGR % | -9.3 | 0.85 | -5.94 | 13.39 | 11.04 | |||||
Unlevered Free Cash Flow, 3 Yr. CAGR % | -9.33 | 1.18 | -6.35 | 12.79 | 11 | |||||
Dividend Per Share, 3 Yr. CAGR % | 4.99 | 4.99 | 8.74 | 22.8 | 30.5 | |||||
Compound Annual Growth Rate Over Five Years | ||||||||||
Total Revenues, 5 Yr. CAGR % | -0.49 | 1.81 | 5.89 | 11.49 | 13.95 | |||||
Gross Profit, 5 Yr. CAGR % | -1.34 | 2.69 | 8.3 | 15.99 | 18.15 | |||||
EBITDA, 5 Yr. CAGR % | -7.06 | -0.75 | 6.66 | 15.86 | 14.73 | |||||
EBITA, 5 Yr. CAGR % | -13.33 | -3.86 | 5.97 | 20.37 | 17.58 | |||||
EBIT, 5 Yr. CAGR % | -13.33 | -3.86 | 5.97 | 20.37 | 17.58 | |||||
Earnings From Cont. Operations, 5 Yr. CAGR % | -1.16 | 7.12 | 12.79 | 16.56 | 18.06 | |||||
Net Income, 5 Yr. CAGR % | -1.59 | 4.61 | 12.62 | 16.53 | 18.04 | |||||
Normalized Net Income, 5 Yr. CAGR % | -9.99 | -5.07 | 6.54 | 22.13 | 18.79 | |||||
Diluted EPS Before Extra, 5 Yr. CAGR % | -0.3 | 5.68 | 13.39 | 16.88 | 18.66 | |||||
Accounts Receivable, 5 Yr. CAGR % | -1.38 | 2.84 | 8.56 | 1.6 | 14.88 | |||||
Inventory, 5 Yr. CAGR % | 6.84 | 7.31 | 11.81 | 20 | 24.32 | |||||
Net Property, Plant and Equip., 5 Yr. CAGR % | 1.18 | 6.9 | 9.87 | 12.98 | 15.07 | |||||
Total Assets, 5 Yr. CAGR % | 1.87 | 3.01 | 5.74 | 10.64 | 10.42 | |||||
Tangible Book Value, 5 Yr. CAGR % | 1.63 | 4.62 | 6.09 | 7.08 | 3.9 | |||||
Common Equity, 5 Yr. CAGR % | 0.65 | 2.81 | 5 | 6.2 | 4.45 | |||||
Cash From Operations, 5 Yr. CAGR % | 1.98 | 0.44 | 1.1 | 45.46 | -22.82 | |||||
Capital Expenditures, 5 Yr. CAGR % | 2.86 | 20.43 | 21.02 | 19.59 | 29.49 | |||||
Levered Free Cash Flow, 5 Yr. CAGR % | -5.55 | 51.7 | 2.66 | -6.92 | 9.79 | |||||
Unlevered Free Cash Flow, 5 Yr. CAGR % | -5.28 | 53.18 | 2.32 | -6.95 | 9.73 | |||||
Dividend Per Share, 5 Yr. CAGR % | 6.19 | 2.96 | 5.15 | 16.47 | 20.79 |
- Stock Market
- Equities
- 4568 Stock
- Financials Daiichi Sankyo Company, Limited
- Financial Ratios
Select your edition
All financial news and data tailored to specific country editions
MarketScreener is also available in this country: United States.
Switch edition















